Stealth gene therapy company.

Providing consultancy services specializing in business development, scientific strategy, partnership/collaborations, and go-to-market strategy in the genomics, population genomics, genomics tools, very high performance compute, diagnostics, and therapeutics space.

Responsible for commercial operations including bringing to market Complete Genomics’ (CG) large-scale sequencing solution competing with Illumina’s X Ten system. Also responsible for technology licensing, corporate strategy, business development, and interactions with BGI (CG parent company). Highlights include:• Demonstrated value of whole-genome sequencing (WGS) by setting up and executing ~20 clinical utility studies comparing WGS to clinical standard of care. Results overwhelmingly showed improved diagnostic yield on CG system resulting in KOL engagement, interest in purchase, and key publications. All Revolocity sales and most of the pipeline originated from this approach.• Closed purchase agreements for multiple systems with high profile clinical institutions.• First year new product sales of $65M to clinical / hospital groups.• Built robust deal pipeline (~$200M near term) and clear path to company profitability.

iKaryos Diagnostic used whole-genome information to provide better diagnostic, prognostic, and therapeutic management decisions for cancer patients. iKaryos was built using technology licensed from a University and developed by a co-founder. We expanded on the technology, built a brand, market and revenue around our diagnostic test, and sold the company in 2011.• Raised seed capital for initial operations. This capital, along with product revenue, was sufficient to run the company through its sale in 2011.• Negotiated and executed international distribution agreements in Asia, the Middle East, and Australia.

Amnestix developed therapeutics for Alzheimer’s and related diseases. The initial technology was licensed from TGEN (Pheonix, AZ) from discoveries linking genetic variations with memory recall. High memory performers and specific genetic alterations that suggested specific therapeutic targets. Existing compounds targeted these pathways and Amnestix was validating and developing these for therapeutic use.• Managed all scientific interactions with TGEN.• Initiated pre-clinical IND enabling studies for repurposed compounds. • Part of three person transaction team that sold the company to Sygnis Pharma AG.

Rinat Neuroscience develops protein therapeutics for neuroscience indications including Alzheimer’s disease, pain, migraine, and other areas. Had a duel role in research and BD. On the research side, had a team of 8 scientists working primarily in Alzheimer’s, Parkinson’s and pain animal models along with a group developing monoclonal antibodies against targets as precursors to therapeutic proteins. On the business development side, inclicensed a number of therapeutic protiens and was part of deal team that sold company to Pfizer.• Executed an all cash acquisition of Rinat by Pfizer as a member of six person transaction team. Was the largest cash transaction for a private biotech at the time.• Identified, negotiated, and executed two in-licensing deals for potential therapeutic proteins. One of these is now in pre-clinical development.• Directed Rinat’s research efforts in migraine, Alzheimer’s disease, Parkinson’s disease, nociceptive pain, neuropathic pain, and other early discovery areas. Alzheimer’s drug (RN1219) is in clinical trials and migraine drug (RN307) is scheduled for a Q1 2007 IND.

Rinat Neuroscience develops protein therapeutics for neuroscience indications including Alzheimer’s disease, pain, migraine, and other areas. Had a duel role in research and BD. On the research side, had a team of 8 scientists working primarily in Alzheimer’s, Parkinson’s and pain animal models along with a group developing monoclonal antibodies against targets as precursors to therapeutic proteins. On the business development side, inclicensed a number of therapeutic protiens and was part of deal team that sold company to Pfizer.• Executed an all cash acquisition of Rinat by Pfizer as a member of six person transaction team. Was the largest cash transaction for a private biotech at the time.• Identified, negotiated, and executed two in-licensing deals for potential therapeutic proteins. One of these is now in pre-clinical development.• Directed Rinat’s research efforts in migraine, Alzheimer’s disease, Parkinson’s disease, nociceptive pain, neuropathic pain, and other early discovery areas. Alzheimer’s drug (RN1219) is in clinical trials and migraine drug (RN307) is scheduled for a Q1 2007 IND.

Deltagen created genetically modified mice to accurately predict targets for human drug development. On the technology side, I was the first employee and set up all laboratory operations, created operational procedures for the high-throughput implementation of mouse knock-outs, prioritized which targets to pursue, and directed phenotypic analysis of knock-out lines. Was responsible for technology evaluation for three acquisitions. • Initiated and negotiated exclusive licenses for Deltagen’s validated targets in rheumatoid arthritis, inflammatory bowel disease, anxiety, and diabetes/metabolic disease.Invented essentially all the technology for high-throughput operations.

Post doc and scientist in the Neuroscience department. Also was an RA at Genentech prior to grad school. • Identified, cloned and biochemically characterized neurturin binding receptor (GFRa2) and demonstrated that RET acts as the signaling component.• Project team leader for Genentech’s lead protein therapeutic for treatment of Parkinson’s Disease (neurturin) leading to development decision.• Invented technology that started Genentech’s genomics efforts (signal sequence trap for cloning of secreted proteins). Resulted in Genentech’s largest single research effort to date.